The Efficacy of Clozapine and Aripiprazole in the Treatment of Schizophrenia in Middle-aged and Young Adults and Impact on Metabolic Syndrome
Objective Explore the efficacy of clozapine and aripiprazole in the treatment of schizophrenia in middle-aged and young adults,as well as their impact on metabolic syndrome.Methods 80 middle-aged and young adults with schizophrenia admitted to Third People's Hospital of Ji'an from April 2022 to April 2023.They were divided into two groups using a random number table method,with 40 patients in each group.The control group received treatment with clozapine,while the observation group received treatment with clozapine combined with aripiprazole.Compare the clinical efficacy,adverse reactions during medication,and changes in positive and negative symptom scale(PANSS)scores and metabolic related indicators between two groups of patients at the end of treatment.Results The total clinical effective rate of the observation group was 92.50%,which was higher than the control group's 75.00%,the difference was statistically significant(P<0.05).At the end of the treatment course,the positive scale score,negative scale score,and general psychopathological score of the observation group were all lower than those of the control group,with significant statistical differences(P<0.05);the body mass index(BMI),fasting blood glucose(FBG),triglycerides(TG),and low-density lipoprotein(LDL-C)levels in the observation group were lower than those in the control group,while high-density lipoprotein cholesterol(HDL-C)levels were higher than those in the control group,with significant statistical differences(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups during medication(P>0.05).Conclusion The combination of clozapine and aripiprazole has a significant effect on the treatment of schizophrenia in middle-aged and young adults,compared to using clozapine alone,it does not significantly affect the metabolic related indicators of patients and has better safety,which is worthy of clinical recommendation.
Middle-aged and young adults with schizophreniaClozapineAripiprazoleEfficacyMetabolize
NETL
NSTL
万方数据
